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Abstract: The frequency and clinical relevance of rare pathogens at the site of periprosthetic infections
of the hip and knee joint and their antibiotic resistance profiles have not yet been assessed in-
depth. We retrospectively analyzed all periprosthetic hip and knee joint infections that occurred
between 2016 and 2020 in a single center in southwest Germany. Among 165 infections, 9.7%
were caused by rare microorganisms such as Veilonella sp., Pasteurella sp., Pantoea sp., Citrobacter
koseri, Serratia marcescens, Parvimonas micra, Clostridium difficile, Finegoldia magna, Morganella
morganii, and yeasts. No resistance to piperacillin/tazobactam, carbapenemes, fluoroquinolones, or
gentamicin was observed. Some bacteria displayed resistance to ampicillin, ampicillin/sulbactam,
and cefuroxime. We present follow-up data of patients with infections due to rare pathogens and
discuss the importance of close, interdisciplinary collaboration between orthopedic surgeons and
clinical microbiologists to carefully select the most appropriate anti-infective treatment regimens for
the increasing number of patients with such infections.
Keywords: hip infection; knee infection; periprosthetic joint infection; antibiotic resistance
1. Introduction
Periprosthetic joint infections (PJI) after hip or knee arthroplasty are accepted to
be a rare but hazardous complication with an overall incidence of 1–2% [1]. Infections
significantly impact the clinical course of affected patients, as prolonged inpatient antibiotic
therapy and repeated surgery are frequently required to effectively treat these conditions.
The orthopedic community has increasingly acknowledged the importance of proper and
timely diagnosis as well as adequate treatment of PJIs in recent years [2]. The causative
pathogen is accordingly an important determinant of the clinical outcome. Indeed, it is
known that multidrug-resistant organisms are associated with a poorer outcome and a
higher risk of treatment failure [3,4].
Numerous studies have sought to investigate the exact epidemiology and microbi-
ological etiology of PJIs in either cohort studies [1,5–8] or analyses of data from national
registries [9–11]. All studies agree that staphylococci represent the most common causative
organisms identified at the sites of PJIs, whereas some geographical differences might be ob-
served [1]. For staphylococcal infections, there is compelling evidence regarding incidence,
resistance patterns, and suggested treatment regimens [5–11]. In contrast, much less is
known about other causative agents giving rise to PJIs, especially with regard to uncommon
microorganisms that some studies summarized under the term “other pathogens” [5–7].
However, their exact identification, resistance profiles, and targeted treatments are certainly
not of minor importance. Information about these rare organisms are currently available
from either single reviews [12] or numerous case reports [13–19].
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To the best of our knowledge, no study has dealt with this topic, yet. Hence, the aim of
the present retrospective study was to describe the microbiological etiology of hip and knee
PJIs in a large cohort at a single center over a 5-year period, with particular emphasis on
rare pathogens that have been described infrequently as agents of PJIs in the peer-reviewed
international literature.
2. Results
Between 2016 and 2020, 1654 arthroplasty surgeries of the hip and knee joint were
performed in the department of the first author. Of that total, 1078 were primary surgeries
(hip: 809, knee: 269), and 411 were carried out due to aseptic reasons (hip: 264; knee: 147).
In total, 165 cases of PJIs were documented during the study period. Of those, 100 in-
fections affected hip prostheses, while 65 prosthetic infections of the knee were diagnosed.
Fifty-six of the hip and fifty-seven of the knee patients, respectively, were not primarily op-
erated on by our department, but were referred to us from other hospitals. There were more
male than female patients and the mean age was 70.8 years (range: 35–89 years; Table 1).
Table 1. Demographic data in a study on the microbiological etiology of hip and knee prosthetic joint
infections at a single center in southwest Germany, 2016–2020.
Treatment Category n = Gender Mean Age (y.)(Min–Max)
Total cohort 165 76 f/89 m 70.8 (35–89)
Hip—total 100 52 f/48 m 72 (35–89)
hip—DAIR 49 22 f/29 m 71.9 (35–89)
hip—2-stage * 51 30 f/19 m 72.1 (35–89)
knee—total 65 24 f/41 m 69.1 (51–87)
knee—DAIR 12 5 f/7 m 69.9 (57–80)
knee—2-stage 53 19 f/34 m 68.9 (51–87)
DAIR: debridement, antibiotics, irrigation, retention (of prosthesis); f: female; m: male; *: 12× spacer implantation,
37× Girdlestone hip; y.: years.
Based on a combination of microbiological techniques, at least one microorganism
was identified in 72.7% of the cases (120/165). There were 99 mono- and 21 polymicrobial
infections. In 45 cases (27.2%), the results were negative (knee: 20/65; hip 25/100); 20 of
the 45 negative cases received a pre-treatment with antibiotics (knee: 8/20; hip: 12/25).
Among the 120 cases with microbiological detection, 148 bacteria belonging to 34 dif-
ferent species could be identified. Gram-positive bacteria accounted for 80.4% (119/148)
and Gram-negative pathogens for 17.6% (26/148) of the cases. Fungal infections were
observed in 3 cases (2.0%). Staphylococci were the most common group of pathogens and
were found in 54.7% of the cases. The distribution of all pathogens is displayed in Table 2.
Of these detected cases, 10.9% were already positive on the Gram stain (18/165). Of
note, in one case, the staining was positive and correlated with positive histological findings
(Type II). The Gram-negative rods seen in the staining of this particular case could not be
cultivated, and a polymerase chain reaction (PCR) assays for bacteria was also negative. In
five cases pathogens were exclusively identified by PCR, while microbiological cultures
remained negative.
Based on our definition, a rare organism was observed in 16 cases (9.7%) (Table 2
and Table 4). There were 10 male and 6 female patients at a mean age of 68 (51–85) years.
The comorbidities of these patients are presented in Table 3. The majority of the patients
suffered from multiple comorbidities. There were 13 bacterial and 3 fungal infections.
Primary surgical indications included primary total hip arthroplasty in eight cases, primary
total knee arthroplasty in seven cases, and an aseptic acetabular cup revision arthroplasty
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in one case. DAIR procedures were carried out in seven cases and two-stage procedures in
nine cases (Table 4) (Figures 1 and 2).
Table 2. Overview of the identified 148 organisms at the sites of 165 periprosthetic hip and knee
joint infections.
Microorganism n (Percentage)
Staphylococcus epidermidis 43 (29.1%)
Methicillin-resistant S. epidermidis (MRSE) 33 (22.3%)
Methicillin-susceptible S. epidermidis (MSSE) 10 (6.8%)
Staphylococcus aureus 26 (17.6%)
Methicillin-resistant S. aureus (MRSA) 2 (1.4%)
Methicillin-susceptible S. aureus (MSSA) 24 (16.2%)
Enterococcus faecalis 13 (8.8%)
Beta-hemolytic streptococci 9 (6.0%)
Escherichia coli 6 (4.0%)
Serratia marcescens 4 (2.7%)
Pseudomonas aeruginosa 4 (2.7%)
Enterococcus faecium 4 (2.7%)
Staphylococcus caprae 3 (2.0%)
Staphylococcus haemolyticus 3 (2.0%)
Enterobacter cloacae 3 (2.0%)
Staphylococcus hominis 3 (2.0%)
Cutibacterium acnes 3 (2.0%)
Staphylococcus warneri 2 (1.3%)
Streptococcus gallolyticus 2 (1.3%)
Parvimonas micra 2 (1.3%)
Candida albicans 2 (1.3%)
Citrobacter koseri/diversus 1 (0.6%)
Pasteurella sp. 1 (0.6%)
Proteus mirabilis 1 (0.6%)
Alpha-hemolytic streptococci (not further specified) 1 (0.6%)
Klebsiella pneumoniae 1 (0.6%)
Staphylococcus capitis 1 (0.6%)
Pantoea sp. 1 (0.6%)
Clostridium difficile 1 (0.6%)
Finegoldia magna 1 (0.6%)
Streptococcus oralis 1 (0.6%)
Enterobacterales (not further specified) 1 (0.6%)
Streptococci–(not further specified) 1 (0.6%)
Veilonella parvula/ tobetsuensis 1 (0.6%)
Candida guilliermondii 1 (0.6%)
Morganella morganii 1 (0.6%)
n: absolute number; sp.: species.
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Table 3. Baseline characteristics and comorbidities of the 16 patients suffering from PJI with rare organisms.
Patient Gender Age Comorbidities
1 f 52 NIDDM, chronic venous insufficiency, hypothyreosis, hepatitis C, drugs abuse
2 m 51 depression
3 f 64 arterial hypertension, obesity
4 f 79 renal insufficiency, heart insufficiency, peripheral arterial obstructive disease, cerebral hemorrhage, atrial fibrillation
5 m 71 arterial hypertension, obstructive sleep apnea syndrome, NIDDM, coronary heart disease with stents implantation, gout, colon cancer
6 m 77 none
7 m 56 splenectomy due to hereditary spherocytosis
8 m 56 NIDDM, coronary heart disease with bypass surgery, anxiety disorder
9 f 82 arterial hypertension, Alzheimer’s disease
10 m 71 arterial hypertension, atrial fibrillation, anxiety disorder
11 m 68 none
12 m 69 none
13 m 85 arterial hypertension, coronary heart disease, atrial fibrillation
14 f 67 renal insufficiency, atrial fibrillation, Ogilvie syndrome
15 m 79 pulmonary hypertension, heart insufficiency,
16 f 63 arterial hypertension, osteoporosis, obesity, stomach stapling operation
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Ampicillin r n.t. n.t. n.t. s s s n.t r i r r i
Ampicillin/sulbactam i n.t. n.t. n.t. s s s n.t s s i i s
Piperacillin s n.t. n.t. n.t. s s s n.t i s s s s
Piperacillin/tazobactam s n.t. n.t. n.t. s s s n.t. s s s s s
Cefuroxime s n.t. n.t. n.t. s s s n.t. s r r r r
Cefpodoxime s n.t. n.t. n.t. s s s n.t. s s s s s
Cefotaxime s n.t. n.t. n.t. s s s n.t. s s s s s
Ceftazidime s n.t. n.t. n.t. s i s n.t. s s s s s
Imipenem s n.t. n.t. n.t. s s s n.t. s s s s s
Meropenem s n.t. n.t. n.t. s s s n.t. s s s s s
Ertapenem s n.t. n.t. n.t. s n.t. s n.t. s s s s s
Ciprofloxacin s n.t. n.t. n.t. s s s n.t. s s s s s
Moxifloxacin s n.t. n.t. n.t. s s s n.t. s s s s s
Gentamicin s n.t. n.t. n.t. s s s n.t. s s s s s
Tigecycline r n.t. n.t. n.t. s n.t. s n.t. s i s s s
Co-trimoxazole s n.t. n.t. n.t. s s s n.t. s s s s s
S: susceptible; i: intermediate susceptible; r: resistant; n.t.: not tested; *: identification through 16S-rRNA PCR. (1), (2), (3), (4): means that this bacterium was detected in 4 different clinical cases; each number
represents one case.
Antibiotics 2021, 10, 882 6 of 17
Antibiotics 2021, 9, x FOR PEER REVIEW 1 of 16 
 
Figure 1. (a,b): Preoperative a.p. and lateral radiographs of the right knee joint of a 71-year-old 
male patient. Notice the osteolyses of the proximal medial tibia and the anterior part of the distal 
femur; (c,d): Intraoperative findings. After removal of the femoral component, pus was evident in 
the femoral canal (Serratia marcescens). An articulating antibiotic-loaded spacer was implanted for 
management of the infection; (e,f): After infection eradication, a condylar-constrained prosthesis 
was re-implanted. 
Figure 1. (a,b): Preoperative a.p. and lateral radiographs of the right knee joint of a 71-year-old
male patient. Notice the osteolyses of the proximal medial tibia and the anterior part of the distal
femur; (c,d): Intraoperative findings. After removal of the femoral component, pus was evident in
the femoral canal (Serratia marcescens). An articulating antibiotic-loaded spacer was implanted for
management of the infection; (e,f): After infection eradication, a condylar-constrained prosthesis was
re-implanted.
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Figure 2. (a): Preoperative a.p. radiographs of the pelvis of a 79-year old female patient with a 
femoral head necrosis and secondary osteoarthritis of the right hip joint; (b): Postoperative radio-
graphs after implantation of a cementless total hip arthroplasty; (c): Local findings 7 days after the 
surgery, indicating an early postoperative infection; (d): Purulent fluid was present in the joint 
(Clostridum difficile). The patient could be successfully treated by DAIR. 
The analysis of the resistance profiles of the identified bacteria (Table 4) did not show 
resistance to piperacillin/tazobactam, carbapenems, fluoroquinolones, or gentamicin. In 
some cases, bacterial strains were resistant to ampicillin, ampicillin/sulbactam, and ce-
furoxime. In four cases of anaerobic bacteria (Clostridium difficile, Finegoldia magna, Par-
vimonas micra, Veillonella spp.), no detailed resistance testing was carried out. 
From the 16 patients, three were lost during follow-up and one passed away due to 
reasons not related to the PJI. Among the remaining 12 patients, three suffered from a 
reinfection with a causative organism different than the one primarily identified. The first 
patient had a reinfection with Escherichia coli (previously Finegoldia magna), the second one 
with methicillin-resistant S. epidermidis (primarily Candida guilliermondii), and the third 
one with methicillin-susceptible Staphylococcus aureus (primarily Serratia marcescens) (Table 
5). All three underwent a two-stage procedure for further eradication of the infection. 
Table 5. Data on surgical and systemic antibiotic treatments and infections in a study on the microbiological etiology of 












Morganella morganii * 
(+ MSSA, E. faecalis) hip primary THA two-stage rifampicin + vancomycin lost unclear 
Veilonella parvula/to-
betsuensis knee primary TKA two-stage levofloxacine 12 yes 
Finegoldia magna hip primary THA DAIR ciprofloxacine 7 no 
Clostridium difficile hip primary THA DAIR rifampicin + ceftriaxone 10 yes 
Pantoea sp. knee primary TKA DAIR rifampicin + ciprofloxacin 13 yes 
Pasteurella sp. knee primary TKA DAIR 
rifampicin + cefurox-
ime/ciprofloxacine 54 yes 
Figure 2. (a): Preoperative a.p. radiographs of the pelvis of a 79-year old female patient with a femoral
head necrosis and secondary osteoarthritis of the right hip joint; (b): Postoperative radiographs
after implantation of a cementless total hip arthroplasty; (c): Local findings 7 days after the surgery,
indicating an early postoperative infection; (d): Purulent fluid was present in the joint (Clostridum
difficile). The patient could be successfully treated by DAIR.
The analysis of the resistance profiles of the identified bacteria (Table 4) did not
show resistance to piperacillin/tazobactam, carbapenems, fluoroquinolones, or gentamicin.
In some cases, bacterial strains were resistant to ampicillin, ampicillin/sulbactam, and
cefuroxime. In four cases of anaerobic bacteria (Clostridium difficile, Finegoldia magna,
Parvimonas micra, Veillonella spp.), no detailed resistance testing was carried out.
From the 16 patients, three were lost during follow-up and one passed away due to
reasons not related to the PJI. Among the remaining 12 patients, three suffered from a
reinfection with a causative organism different than the one primarily identified. The first
patient had a reinfection with Escherichia coli (previously Finegoldia magna), the second one
with methicillin-resistant S. epidermidis (primarily Candida guilliermondii), and the third one
with methicillin-susceptible Staphylococcus aureus (primarily Serratia marcescens) (Table 5). All
three underwent a t o-stage procedure for further eradication of the infection.
Antibiotics 2021, 10, 882 8 of 17
Table 5. Data on surgical and systemic antibiotic treatments and infections in a study on the microbiological etiology of hip and knee prosthetic joint infections at a single center in
southwest Germany, 2016–2020.






(+ MSSA, E. faecalis) hip primary THA two-stage rifampicin + vancomycin lost unclear
Veilonella parvula/tobetsuensis knee primary TKA two-stage levofloxacine 12 yes
Finegoldia magna hip primary THA DAIR ciprofloxacine 7 no
Clostridium difficile hip primary THA DAIR rifampicin + ceftriaxone 10 yes
Pantoea sp. knee primary TKA DAIR rifampicin + ciprofloxacin 13 yes
Pasteurella sp. knee primary TKA DAIR rifampicin +cefuroxime/ciprofloxacine 54 yes
Parvimonas micra hip primary THA two-stage moxifloxacine 42 yes
Parvimonas micra hip primary THA two-stage ciprofloxacine 8 yes
Citrobacter koseri/diversus hip primary THA two-stage meropenem + ciprofloxacine lost unclear
Serratia marcescens knee primary TKA two-stage ciprofloxacine 58 yes
Serratia marcescens hip primary THA DAIR rifampicin + meropenem/ciprofloxacine 34 yes
Serratia marcescens hip acetabular cup revision DAIR rifampicin + meropenem/ciprofloxacine 36 yes
Serratia marcescens knee primary TKA two-stage ciprofloxacine 6 no
Candida albicans *
(+ E. coli, E. faecium) knee primary TKA two-stage
meropenem + teicoplanin +
fluconazole lost unclear
Candida albicans hip primary THA DAIR fluconazole exitus n.r.
Candida guilliermondii knee primary TKA two-stage voriconazole 19 no
THA: total hip arthroplasty; TKA: total knee arthroplasty; DAIR: debridement, antibiotics, irrigation, retention of prosthesis; *: polymicrobial infection; n.r.: not relevant.
Antibiotics 2021, 10, 882 9 of 17
3. Discussion
The aim of the present study was to determine the occurrence of rare microorganisms
at the site of hip and knee PJIs and evaluate their antibiotic resistance patterns at a single
center. Our results demonstrate that such uncommon pathogens accounted for 9.7% of all
cases. None of these organisms was multi-drug resistant. However, in 25% of the cases,
that were followed up, reinfections occurred with organisms other than those primarily
identified.
The microbiological spectrum at the sites of PJIs, and in some cases their resistance
profile, has been described in various studies. In a retrospective single-center study, Rafiq
et al. found that coagulase-negative staphylococci were the most common organism in 67%
of the cases in a cohort of 337 infected THAs [7]. “Other” organisms were responsible for 5%
of the cases. Similar findings were described by Nickinson et al. at the sites of 121 infected
knee arthroplasties [6]. Coagulase-negative staphylococci were the dominant group in
49% of the cases, whereas “other” organisms were seen in 25% of the cases. Drago et al.
evaluated the microbiological findings of 429 PJIs of the hip and knee [5]. Staphylococci
were the most frequent organism in 66.6% of the cases, followed by Enterobacteriaceae and
Cutibacterium acnes [7]. There were no differences in the findings between hip and knee
PJIs. Among the “rarely” identified organisms, Acinetobacter sp. were observed in 4 cases,
Corynebacterium species in 10, Candida species in 1, and other anaerobes in 9 infections. In a
very detailed retrospective study of 294 hip and knee PJI cases, Tsai et al. reported that the
most common pathogenic organism was methicillin-susceptible S. aureus (26.5%), followed
by coagulase-negative staphylococci (14.3%) [1]. Culture-negative findings were present in
27.2% of the cases. A variety of rare organisms, such as Prevotella species, Parvimonas micra,
Salmonella enterica, and Morganella morganii could be identified. Interestingly, fungal and
Mycobacterium infections were observed in 1.7% of the cases.
To the best of our knowledge, the term “rare” has not yet been unambiguously
defined in the literature with regard to orthopedic infections. Several terms, such as “rare”,
“atypical”, and “unusual”, have been used for the description of organisms that are not
frequently identified at the sites of PJIs [12,18,20,21]. Caution must be exercised when trying
to propose such a definition because rigorous scientific and clinical criteria are lacking, and
such criteria might vary among different medical disciplines. The present definition used
here sought solely to identify the “true” rare organisms; however, we cannot disregard
the fact that under other circumstances (geographical differences, larger/smaller cohorts,
etc.) the rate of rare organisms might differ from the one identified in the present study.
Especially the geographical differences are of great importance. Aggarwal et al. evaluated
all PJIs treated over a period of 12 years at two referral centers: one in Europe and the other
in the United States [22]. The incidence of methicillin-resistant staphylococcal species, and
particularly S. aureus, was significantly higher in the US than in Europe. Likewise, 27%
of the Enterococcus infections were vancomycin-resistant in the US, whereas no isolates in
Europe showed such resistance.
There are various possible causes for the increasing detection of rare organisms. First
of all, the number of revision arthroplasty surgeries is increasing worldwide. Even if
the particular revision rates stay the same, the absolute numbers will increase, and thus
the possibility of identifying more pathogenic organisms. Over the past 10–15 years, a
significant number of new bacterial species or subgroups within known species has been
described [23]. The cases that were previously just called, for example, “staphylococci
with no further differentiation” can nowadays be classified into numerous subgroups [23].
Furthermore, new microbiological detection methods have been developed and established
in clinical practice. At the sites of implant infections, the use of sonication is recognized
to have additional advantages with regard to sensitivity and specificity compared to
the gold standard bacterial cultures [24,25]. The use of molecular biological techniques,
such as polymerase chain reaction (PCR), also count as an enhancement to diagnostic
measures despite their susceptibility to contamination and inhibition [26–28]. Prolonged
cultivation periods in the range of ≥ 14 days compared with standard cultures over 7 days
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demonstrated an increase in the detection rate by more than 25% [29], although more
recent studies question the necessity of extended culture duration in acute periprosthetic
hip and knee joint infections [30]. Last but not least, more tissue samples are nowadays
taken during surgery and sent for further microbiological examination, thus increasing the
possibility of a positive microbiological result. The Infectious Diseases Society of America
(IDSA) recommends submitting at least three and optimally five or six periprosthetic tissue
samples for aerobic and anaerobic culture [31].
Regarding the results presented here, it is important not to over-interpret the relative
frequency of each identified organism. Such values are dynamic and greatly depend on
“trends” of diagnostics and treatment. The more revision surgeries are performed, the
more tissue samples are taken and investigated, and with the improvement of diagnostic
measures, the higher is the possibility of identifying more pathogenic agents. Our study
acknowledges the increasing relevance of these lesser known pathogens with regard to
musculoskeletal infections and in particular PJIs. The origin of infections caused by these
pathogens frequently remains unknown, but might have been hematogenous in some cases.
Indeed, many of these bacteria belong to the physiological microbiota environment in other
parts of the human body, as is exemplarily shown in Table 6 for some of the pathogens
detected in our study.
Data in the literature on PJIs are scarce for the rare pathogens found in our study.
Some of these organisms (P. micra) have been described at the sites of PJIs following dental
procedures [32], although there is considerable debate as to whether an antibiotic treatment
should be provided in the prevention of those infections [33]. Others, such as F. magna,
have been seen either at the site of polymicrobial infections [34] or in a single report of
two cases [13]. PJIs due to Veilonella species [14,16,35], Pantoea species [19], Pasteurella
species [15,36–41], and Citrobacter [42,43] are exceedingly rare. Of note, most of these
bacteria (9/13) are Gram-negative. It is generally accepted that the eradication of Gram-
negative PJIs can be difficult, with success rates ranging between 52 and 75%, depending
on whether DAIR or two-stage procedures have been carried out [44,45]. Similar results
have been reported for fungal PJIs. At the sites in 31 cases, Azzam et al. reported that
70% of the patients treated with DAIR suffered from infection persistence and required
resection arthroplasty [46]. However, only 9 of the 29 patients undergoing resection
arthroplasty underwent eventual eradication of the infection and delayed reconstruction.
In a systematic review of surgical treatments (one-stage, two-stage, resection arthroplasty,
DAIR) and clinical outcomes, Fusini et al. observed total success in 63% of the cases [47].
Kuiper et al. described an 85% success rate when two-stage exchange arthroplasty was
performed [48]. Overall, it is apparent that all these scarce reports with a discrepancy of
outcomes do not allow for a generalization of conclusions.
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Table 6. Microbiological information about the rare causative bacteria.
Bacterium Gram Stain Aerobic/Anaerobic Family Microscopic Morphology Physiologic Environment
Morganella morganii negative facultatively anaerobic Morganellaceae rods normal flora in intestinal tracts of humans, mammals,and reptiles
Veilonella sp. negative anaerobic Veilonellaceae cocci normal flora in intestinal tracts and oral mucosa frommammals
Finegoldia magna positive anaerobic Clostridia cocci normal flora on human skin, mucous membranes
Clostridium difficile positive anaerobic Clostridioides rods normal flora in intestinal tracts of humans
Pantoea sp. negative facultatively anaerobic Erwiniaceae rods plant surfaces, seeds, fruit, animal/human feces
Pasteurella sp. negative facultatively anaerobic Pasteurellaceae rods oral flora from cats and dogs
Parvimonas micra positive anaerobic Peptoniphilaceae cocci oral flora in humans
Citrobacter koseri/diversus negative facultatively anaerobic Enterobacteriaeae rods normal flora from human and animal digestive tracts
Serratia marcescens negative facultatively anaerobic Yersiniaceae rods human and animal digestive tracts, dust, soil, surfacewaters
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The usual perioperative antibiotic prophylaxis involves a first- or second-generation
cephalosporin (cefazolin or cefuroxime) regardless of the type of surgery (primary or
revision) or comorbidities of the patient [49]. This choice is often appropriate because
Gram-positive bacteria are responsible for the majority of PJIs [5]. On the other hand,
difficult-to-treat PJIs are becoming an increasing problem [50,51], and such antibiotic
therapy might not be effective against these infections. The resistance patterns of the
organisms in the present study show that these organisms were not multi-drug resistant and
were susceptible to a wide range of tested antibiotics in vitro. In single cases, resistance was
seen against ampicillin and cefuroxime, mainly in Serratia marcescens, which is intrinsically
resistant to ampicillin. No resistance was observed against fluoroquinolones, and especially
ciprofloxacin, which is regarded to be a cornerstone in the treatment of Gram-negative
PJI [52]. Despite the antibiotic susceptibility of these organisms, 25% of the patients
that were followed up suffered from reinfections with an organism other than primarily
identified. We do not regard this as a failure of treatment. It is generally accepted that
successful treatment of PJI does not depend solely on systemic antibiotic therapy, but
also on other factors such as surgical debridement, local antibiotic therapy, or patient
comorbidities. In particular, the presence of certain comorbidities such as diabetes mellitus,
obesity, hypertension, hepatitis C, drug abuse, and heart and renal disorders are recognized
to be risk factors for the emergence of PJI in general [1,8]. The sole role of each comorbidity
in the emergence of a PJI caused by a rare organism is, however, unclear, and difficult to
evaluate based on the small number of patients identified in the present work as well as
the limited data in the literature.
Several limitations of our study are presented for consideration. The study was
retrospective, with all the drawbacks of such a design. Due to this design, we were not able
to determine which antibiotics were previously received by patients who were referred to
us. The presently suggested definition of “rare organisms” is a first attempt, and might be
further modified in the future. The 16 cases evaluated did not allow for a generalization
of conclusions about the pathogenicity of these organisms at the sites of PJIs. Finally,
further progress in infectious disease diagnostics will certainly change and improve our
understanding of the microbiological etiology of PJIs in the foreseeable future, e.g., by the
introduction of metagenomic sequencing in routine clinical practice [53].
4. Materials and Methods
A retrospective analysis of the internal arthroplasty data bank of the department of
the first author was performed for identification of all periprosthetic hip and knee joint
infections during the time period 2016–2020. Inclusion criteria were all revisions that
were performed due to septic reasons, with complete documentation of all diagnostic
measures. Patients that had revision arthroplasty surgery for any other reasons, and those
with insufficient or incomplete documentation, were excluded from the study. Due to the
retrospective study design, approval by the local ethics committee was unnecessary.
The primary aim of the study was to identify the rates and resistance patterns of
rare pathogenic organisms at the sites of hip and knee PJIs. The secondary goal was to
determine infection eradication rates at the sites of these rare infections.
Infections included in this analysis were defined by the criteria of the Musculoskeletal
Infection Society (MSIS) [54]. Preoperatively, a joint aspiration was performed to differ-
entiate aseptic from septic prosthesis loosening, except for those patients whose positive
blood cultures confirmed hematogenous infections or who presented with systemic sepsis
signs and were immediately operated on. A further exclusion concerned patients who
had fistulas. In these cases, we preferred to take direct tissue samples during surgery.
If joint aspiration revealed negative microbiological findings, but clinical, laboratory or
radiological findings pointed strongly to the presence of an infection, an arthroscopic or
open biopsy was performed prior to the prosthesis revision.
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4.1. Surgical Management
All patients, suffering from an early or acute hematogenous PJI were initially treated by
means of DAIR (debridement, antibiotics, irrigation, retention (of prosthesis)). All infected,
necrotic, or ischemic tissue layers were debrided. Removable prosthetic components (knee:
polyethylene insert; hip: acetabular cup insert, femoral head) were always exchanged. A
pulsatile lavage with at least 5 L Ringer’s solution was also performed.
All patients with a late PJI and those having had two unsuccessful DAIR surgeries
with persistence of infection [55] underwent a two-stage procedure. In the first surgery,
all prosthetic components including cement were removed, and all infected, necrotic, or
ischemic tissue layers were debrided. A pulsatile lavage with at least 5 L Ringer’s solution
was always performed.
At the sites of hip infections, the primary goal has always been to implant an antibiotic-
loaded spacer. In these cases, the spacer was intraoperatively produced by means of
commercially available molds (Stage OneTM, Fa. ZimmerBiomet, Freiburg im Breisgau,
Germany). However, patients with a reduced medical condition and unable to avoid
putting any weight on the operated extremity postoperatively, those who suffered from
large osseous defects of the proximal femur or acetabulum, and those who needed a
transfemoral approach for the safe removal of the femoral stem were deemed better suited
for a resection arthroplasty (Girdlestone procedure) due to the higher theoretical risk of a
secondary spacer dislocation or fracture during the interim phase [56]. In these cases, 2–3
antibiotic-loaded beads (Septopal®, Fa. ZimmerBiomet, Freiburg im Breisgau, Germany)
were inserted into the acetabulum and the femoral canal.
Regarding knee infections, the presence of bone defects, according to the Anderson
Orthopedic Research Institute (AORI) bone defect protocol [57], helped us decide whether
an articulating or a static spacer should be implanted. All patients with bone defects
I-IIA were treated with an articulating spacer (Copal knee molds, Fa. Hereaus, Wehrheim,
Germany). Patients suffering from bone defects IIB-III were treated with a static spacer.
This spacer was molded individually according to the particular joint space geometry.
For the intraoperative production of hip and knee spacers, commercially available
antibiotic-loaded bone cement was used, loaded either with gentamicin or gentamicin +
clindamycin (Palacos® R + G/Copal® G + C, Fa. Hereaus, Wehrheim, Germany). Depend-
ing on the particular causative organism and its resistance profile, 2 g vancomycin/40 g
bone cement were additionally incorporated into the cement in certain cases.
After the operation, an immediate, systemic antibiotic therapy was started—either
specific if the causative organism was preoperatively known, or a calculated therapy with
1.5 g cefuroxime intravenously (thrice daily) if the causative organism were unknown, and
adjusted if necessary during the further course. All patients received an antibiotic therapy
over 6 weeks, consisting of administration 3–4 weeks intravenously and 2–3 weeks orally.
All knee joints with a static spacer were immobilized in a cast in full extension. Patients
with an articulating spacer were allowed to flex their knee as tolerated. All patients (hip
and knee) were allowed to walk on crutches with no weight on the operated extremity.
Six weeks after the spacer implantation or the Girdlestone procedure, the antibiotic
therapy was paused for 7–10 days and the serum inflammation parameters (C-reactive
protein, blood cell count) controlled. If the laboratory parameters were normal, a prosthe-
sis reimplantation was then planned if the wound had healed and the general medical
condition of the patient allowed for it. The types of implants used were chosen based
on the amount of bone loss and quality. A joint aspiration was not routinely carried out
prior to spacer explantation and prosthesis reimplantation because data in the literature
demonstrated no benefit from such a measure [58,59].
4.2. Microbiological and Histopathological Diagnostic Techniques
Tissue samples from at least 5 different locations along with joint fluid (when present)
were taken and sent for further microbiological and histological examination. All samples
were sent within 30 min to our Microbiologic and Pathologic Institute.
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Upon histopathological analysis, all samples were classified in accordance with the
system of Krenn and Morawietz to provide an estimate of the probability of infection [60].
Upon receipt for microbiological analysis, all samples were immediately processed
and subjected to microscopic examination using a Gram stain. Different agar media and
enrichment broths were used for microbiological culture, i.e., Columbia blood agar and
MacConkey agar for aerobic culture, and Schaedler agar plates for anaerobic culture.
Thioglycolate bouillons of each sample were inspected daily for an incubation period of
7 days until 2018, which was then prolonged to 14 days per sample to account for any slowly
growing bacteria [29]. Culture-grown colonies of bacteria or fungi were subjected to further
analysis using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry or the VITEK® 2 system (BioMérieux; Nürtingen, Germany) for species
identification. Antimicrobial susceptibility testing was performed using either the VITEK®
2 system or agar disc diffusion tests, as appropriate. Samples without microbiological
growth but with suspicious histopathology results were further analyzed by a broad-range
16S rRNA PCR to assess the presence of bacterial nucleic acids. PCR-positive samples were
subsequently sequenced to reach identification at the genus or species level.
For the organisms exclusively identified by 16S PCR, no resistance testing could be per-
formed. All laboratory procedures were in accordance with the microbiological-infectiological
quality standards (MiQs) of the German Society of Hygiene and Microbiology.
4.3. Definition of Rare Organisms
The term “rare” has not been unambiguously defined with regard to PJI. Therefore, we
had to subjectively set classification criteria. This decision was made by both the treating
orthopedic surgeons and the microbiologists involved in the management of these cases.
First of all, we decided not to define the rarity of the organisms solely based on their
occurrence in our study, to avoid setting-specificity. Moreover, we sought to distinguish
between the truly rare organisms and the “unusual” or “atypical” ones. The latter organ-
isms would probably be those that are frequently identified at the sites of other infections
(e.g., pneumonia, urinary tract infections), but not typically at the site of a PJI. In our
opinion, however, they do not warrant automatic classification as “rare” and rather should
be named “unusual” or “atypical”. Last but not least, we searched the international peer-
reviewed literature in English for every pathogenic organism detected in the present study
in order to identify whether there were many or only a few scientific publications about
that particular organism.
Following these preparatory steps, an organism was defined as “rare” if (1) it was not
typically associated with PJI, or (2) it had only been described in a maximum of 10 case
reports or a small case series about PJIs in the English literature. An exclusion applied here
to fungal infections, because these are the only organisms that are recognized to be rare
causative organisms in PJIs according to the literature, with an incidence rate of less than
1% [46–48].
5. Conclusions
To our knowledge, the present study is the first that sought to determine the occurrence
of rare organisms and their antibiotic resistance patterns at the sites of hip and knee PJIs.
Such pathogens accounted for approximately 10% of all infections. No organism was
multi-drug resistant or difficult to treat. Although orthopedic surgeons are responsible for
the practical treatment, these findings call for the establishment of close, interdisciplinary
collaboration with clinical microbiologists and infectious disease specialists to carefully
select the most appropriate anti-infective treatment options for patients suffering from PJIs
due to such less-common causative agents.
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